medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2016; 15 (2)


Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis

Hilscher M, Enders FB, Carey EJ, Lindor KD, Tabibian JH

Idioma: Ingles.
Referencias bibliográficas: 21
Paginas: 246-253
Archivo PDF: 162.46 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert review of gastroenterology &hepatology 2013; 7: 103-14.

  2. Gupta A, Bowlus CL. Primary sclerosing cholangitis: etiopathogenesis and clinical management. Frontiers in bioscience 2012; 4: 1683-705.

  3. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Seminars in liver disease 2006; 26: 22-30.

  4. Tabibian JH, O’Hara SP, Splinter PL, Trussoni CE, Larusso NF. Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis. Hepatology2014; 7: 103-14.

  5. Tabibian JH, Lindor KD. Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis. Journal of Analytical Oncology 2012;1: 50-5.

  6. Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Digestive and liver disease 2010; 42: 390-400.

  7. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58: 1538-44.

  8. Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA. Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Ann Hepatol 2014; 13: 384-9.

  9. Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, LaRusso NF, et al. A revised natural history model for primary sclerosing cholangitis.Mayo Clinic proceedings 2000; 75: 688-94.

  10. Wiesner RH. Moving toward evidence-based liver allocation in patients with primary sclerosing cholangitis.Liver transplantation 2013; 19: 241-2.

  11. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

  12. Olsson R, Broome U, Danielsson A, Hägerstrand I, Järnerot G, Lööf L, Prytz H, et al. Spontaneous course of symptoms in primary sclerosing cholangitis: relationships with biochemical and histological features. Hepatogastroenterology 1999; 46: 136-41.

  13. Balasubramaniam K, Wiesner RH, LaRusso NF. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity.Gastroenterology 1988; 95: 1395-8.

  14. Stanich PP, Bjornsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Digestive and liver disease 2011; 43: 309-13.

  15. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Alimentary pharmacology & therapeutics 2013; 37: 604-12.

  16. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis.Hepatology 2010; 51: 660-78.

  17. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).VirchowsArchiv 1978; 379: 103-12.

  18. NguJH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clinical gastroenterology andhepatology 2011; 9: 1092-7; quiz e135.

  19. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013; 58: 329-34.

  20. Corpechot C, Gaouar F, El Naggar A, Kemgang A, Wendum D, Poupon R, Carrat F, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014; 146: 970-9; quiz e15-6.

  21. Tabibian JH, Lindor KD. Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). Hepatology 2014; 60: 785-8.




2020     |     www.medigraphic.com